Ravi RetnakaranByung Soo YounYing LiuAnthony J G HanleyNam Seok LeeJi Woo ParkEun Sun SongVivian VuWi KimRungsunn TungtrongchitrPeter J. HavelMichael M. SwarbrickCollin ShawGary SweeneyYork UniversityMount Sinai Hospital of University of TorontoUniversity of TorontoKorea UniversityMahidol UniversityUniversity of California, DavisALPCO Diagnostics2018-07-122018-07-122008-12-01Clinical Endocrinology. Vol.69, No.6 (2008), 885-89313652265030006642-s2.0-55949117816https://repository.li.mahidol.ac.th/handle/20.500.14594/19459Objective: Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters. Design, patients and measurements: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers. Results: The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086). Conclusions: Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states. © 2008 The Authors.Mahidol UniversityMedicineArticleSCOPUS10.1111/j.1365-2265.2008.03264.x